https://wikimd.com/index.php?action=history&feed=atom&title=MDMB-BINACAMDMB-BINACA - Revision history2026-04-23T19:59:02ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.com/index.php?title=MDMB-BINACA&diff=6427836&oldid=prevPrab: CSV import2025-03-05T06:14:58Z<p>CSV import</p>
<p><b>New page</b></p><div>{{Short description|Synthetic cannabinoid}}<br />
{{Drugbox<br />
| verifiedfields = changed<br />
| verifiedrevid = 477002693<br />
| image = MDMB-BUTINACA_structure.png<br />
| image2 = <br />
| IUPAC_name = Methyl (2S)-2-[[1-(cyclohexylmethyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate<br />
| CAS_number = 1971007-92-7<br />
| PubChem = 129631792<br />
| ChemSpiderID = 52085456<br />
| UNII = <br />
| C=21<br />
| H=29<br />
| N=3<br />
| O=3<br />
| smiles = CC(C)(C)[C@@H](C(=O)OC)NC(=O)c1nn(CC2CCCCC2)c3ccccc13<br />
| StdInChI = 1S/C21H29N3O3/c1-21(2,3)18(20(26)27-4)22-19(25)17-16-10-6-5-9-15(16)14-24(23-17)13-11-12-7-8-12/h5-6,9-10,12,18H,7-8,11,13-14H2,1-4H3,(H,22,25)/t18-/m0/s1<br />
| StdInChIKey = <br />
}}<br />
<br />
'''MDMB-BINACA''' is a synthetic [[cannabinoid]] that has been used as a designer drug. It is a potent agonist of the [[CB1 receptor]], which is part of the [[endocannabinoid system]].<br />
<br />
==Chemical Structure and Properties==<br />
MDMB-BINACA is chemically classified as an indazole-based synthetic cannabinoid. Its full chemical name is methyl (2S)-2-[[1-(cyclohexylmethyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate. The compound features a cyclohexylmethyl group attached to the indazole core, which is a common structural motif in many synthetic cannabinoids.<br />
<br />
[[File:MDMB-BUTINACA_structure.png|Structure of MDMB-BINACA|thumb|right]]<br />
<br />
The molecular formula of MDMB-BINACA is C<sub>21</sub>H<sub>29</sub>N<sub>3</sub>O<sub>3</sub>, and it has a molecular weight of 371.48 g/mol. The compound is typically found as a white powder and is soluble in organic solvents.<br />
<br />
==Pharmacology==<br />
MDMB-BINACA acts as a potent agonist at the [[CB1 receptor]], which is primarily located in the [[central nervous system]]. Activation of this receptor by MDMB-BINACA leads to effects similar to those of [[tetrahydrocannabinol]] (THC), the active component of [[cannabis]]. These effects can include altered perception, mood changes, and impaired motor function.<br />
<br />
The potency of MDMB-BINACA at the CB1 receptor is significantly higher than that of THC, which can lead to more pronounced effects and a higher risk of adverse reactions. Users of synthetic cannabinoids like MDMB-BINACA may experience severe side effects, including [[anxiety]], [[paranoia]], [[tachycardia]], and [[hypertension]].<br />
<br />
==Legal Status==<br />
Due to its potential for abuse and lack of medical use, MDMB-BINACA has been classified as a controlled substance in many countries. In the [[United States]], it is listed as a Schedule I substance under the [[Controlled Substances Act]]. Similarly, it is controlled under the [[Misuse of Drugs Act 1971]] in the [[United Kingdom]].<br />
<br />
==Synthesis==<br />
The synthesis of MDMB-BINACA involves the reaction of an indazole core with a cyclohexylmethyl group and a dimethylbutanoate moiety. The process typically requires specialized knowledge in organic chemistry and access to controlled precursors.<br />
<br />
==Health Risks==<br />
The use of MDMB-BINACA is associated with significant health risks. Acute intoxication can lead to severe psychological and physiological effects, including [[hallucinations]], [[seizures]], and [[cardiovascular complications]]. Long-term use may result in dependence and withdrawal symptoms.<br />
<br />
==Related Pages==<br />
* [[Synthetic cannabinoids]]<br />
* [[Cannabinoid receptor]]<br />
* [[Designer drugs]]<br />
* [[Drug policy]]<br />
<br />
[[Category:Synthetic cannabinoids]]<br />
[[Category:Designer drugs]]<br />
[[Category:Indazolecarboxamides]]</div>Prab